FDA OKs ADHD Medication

SEPTEMBER 15, 2017
The FDA has approved an extended-release amphetamine (Adzenys ER, Neos Therapeutics) oral suspension for treating attention-deficit hyperactivity disorder (ADHD), according to a company press release.1  Once commercially available, Adzenys ER oral suspension will be the third Neos extended release product for the treatment of ADHD, joining Adzenys XR-ODT® (amphetamine) Extended-Release Orally Disintegrating Tablets and Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets.

Adzenys ER, formerly referred to as NT-0201, is a once-daily, extended-release liquid medication that does not require refrigeration or reconstitution at the pharmacy level, according to the release.

“It is important for physicians to have a wide choice of medicines to help our patients with ADHD manage their symptoms,” Michael Feld, MD, a Northbrook, IL-based Child, Adolescent, and Adult Psychiatrist specializing in the treatment of ADHD said in a press release. “As a once-daily liquid formulation, Adzenys ER can play a role in meeting the individual needs of my patients.”

Adzenys ER is expected to become available in early 2018.

Reference
Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older (news release). Dallas, TX. http://investors.neostx.com/phoenix.zhtml?c=254075&p=RssLanding&cat=news&id=2301045. Accessed September 15, 2017. 

0
Plantsvszombies.info Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.
узнать больше

источник